COVID-19 Vaccines & Compensation Remedies
COVID-19 vaccine injuries are not covered by the Vaccine Injury Compensation Program (VICP). Instead, claims are directed to the Countermeasures Injury Compensation Program (CICP) under the PREP Act. This page explains why that happened, what the CICP provides, and why many argue the VICP is the more appropriate forum.
Part I: When Were COVID Vaccines Authorized and Deployed?
The COVID-19 vaccines were developed and deployed at unprecedented speed. On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued the first Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. One week later, on December 18, 2020, the FDA issued an EUA for the Moderna vaccine. The Johnson & Johnson vaccine received EUA authorization on February 27, 2021.
Vaccination began immediately. The first publicly documented COVID-19 vaccination in the United States occurred on December 14, 2020, just days after the first EUA was granted. Within months, millions of doses were administered across the country. Over the next several years, hundreds of millions of COVID-19 vaccine doses were administered in the United States, and billions worldwide.
When a medical product is deployed at that scale, even extremely rare adverse events will occur in a small fraction of recipients. That reality does not undermine the overall safety or effectiveness of the vaccines. It reflects basic statistical principles: when large populations are vaccinated, rare events become visible.
The question is not whether rare injuries were possible. The question is: what compensation system was in place to address them?
That is where the structural issue begins.
Part II: What Role Did Congress Play in the COVID Vaccine Rollout?
The rapid development and deployment of the COVID-19 vaccines did not occur in a vacuum. It was the result of a coordinated federal effort known as Operation Warp Speed, announced by the White House on May 15, 2020.
Operation Warp Speed was designed to accelerate vaccine development, manufacturing, and distribution during the public health emergency. It combined federal funding, regulatory coordination, advance purchase agreements, and logistical planning to make large-scale vaccination possible in record time.
Congress played a central role in this effort.
In March 2020, Congress passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which provided billions of dollars in emergency funding to support vaccine development, procurement, and distribution. Additional appropriations followed, directing further federal resources toward manufacturing scale-up and nationwide dissemination.
By mid-2020, federal agencies were entering into advance purchase agreements with vaccine manufacturers, committing public funds before clinical trials were complete. The goal was clear: once authorized, vaccines would be available immediately and in massive quantities.
That goal was achieved.
Within days of the first Emergency Use Authorization in December 2020, vaccines were being shipped nationwide. Within months, tens of millions of Americans had received at least one dose. Within a year, the number of doses administered had reached into the hundreds of millions.
This scale matters.
When a government funds, promotes, and administers a vaccine to an entire population at this speed and magnitude, it is statistically predictable that a small percentage of recipients will experience serious adverse events. That expectation does not undermine vaccine safety. It reflects basic mathematics: rare events become visible when applied to large populations.
Congress authorized and funded one of the largest vaccination campaigns in modern history. What Congress did not do, however, was explicitly ensure that individuals who might suffer rare but serious injuries from that mass administration would have access to the Vaccine Injury Compensation Program.
This omission is notable because Congress had historical guidance available. During the 1976 swine flu vaccination campaign, lawmakers addressed vaccine-related injuries through dedicated compensation legislation after adverse events emerged. The concept of pairing mass vaccination with a structured compensation mechanism was not new.
In practical terms, incorporating COVID vaccines into the VICP would not have required a complex statutory overhaul. Congress could have amended the Vaccine Act to include COVID vaccines as covered vaccines and imposed a modest excise tax—such as $0.75 per dose—to fund the Vaccine Injury Compensation Trust Fund. The legislative change necessary to accomplish this would have been brief and technically straightforward.
Whether that omission was an oversight, a prioritization decision made during crisis response, or a reflection of competing legislative pressures is a matter of interpretation. What is clear is that COVID vaccines were deployed nationwide without being placed inside the existing no-fault compensation structure that Congress had previously established for other vaccines.
The structural implications of that decision become clearer when examining what compensation pathway was available instead.
Part III: Why Are COVID Vaccines Not in the VICP?
The Vaccine Injury Compensation Program is not a general vaccine injury fund. It is a statutory program governed by the National Childhood Vaccine Injury Act of 1986. For a vaccine to be covered under the VICP, it must be included within the framework of that statute and listed as a covered vaccine under the program’s regulations.
COVID-19 vaccines were not added to the VICP at the time they were deployed.
Instead, they were treated as covered countermeasures under a separate legal framework: the Public Readiness and Emergency Preparedness Act, commonly referred to as the PREP Act.
This distinction is critical.
The VICP applies to vaccines that Congress has designated as covered under the Vaccine Act. When those vaccines are administered, claims for injury must proceed through the VICP before any civil litigation can be considered.
COVID vaccines, however, were rolled out under emergency authority and classified as countermeasures during a declared public health emergency. That classification triggered a different legal pathway for injury claims—one that does not run through the VICP.
As a result, individuals alleging injury from COVID vaccines were directed into a separate compensation system, rather than the Vaccine Injury Compensation Program.
This was not because the VICP lacked the structural capacity to evaluate COVID-related claims. The VICP already adjudicates complex vaccine injury cases involving evolving medical science, rare neurological disorders, and immune-mediated conditions. The program was designed to handle scientific uncertainty and individualized causation.
Rather, the exclusion was the result of how the vaccines were legally categorized during the emergency response.
The practical effect of that categorization is significant. When COVID vaccines were deployed to hundreds of millions of people, they were not paired with the same compensation framework that applies to other routinely administered vaccines.
To understand what replaced the VICP in this context, it is necessary to examine the PREP Act and the compensation system attached to it.
Part IV: What Is the PREP Act and How Does It Affect COVID Vaccine Injury Claims?
The legal framework that governed COVID-19 vaccines during the public health emergency was the Public Readiness and Emergency Preparedness Act, commonly known as the PREP Act.
The Secretary of Health and Human Services issued a PREP Act declaration for COVID-19 countermeasures on February 4, 2020. That declaration, published in the Federal Register in March 2020, designated certain medical products—including vaccines—as covered countermeasures during the declared emergency.
Under the PREP Act, manufacturers, distributors, program planners, and administrators of covered countermeasures receive broad immunity from civil liability for claims of loss relating to the use of those countermeasures.
In practical terms, this meant that traditional civil lawsuits alleging injury from COVID-19 vaccines were largely barred. Except in narrow circumstances involving willful misconduct—an extremely high legal standard—courts have dismissed COVID vaccine injury lawsuits at early stages based on PREP Act immunity.
The PREP Act declaration for COVID countermeasures was amended multiple times over the course of the pandemic, extending liability protections as vaccination efforts continued. These amendments reinforced the legal channeling of injury claims away from civil courts.
It is important to understand that immunity under the PREP Act was not unique to vaccines. The statute applies to a range of emergency medical countermeasures during declared public health emergencies. Its purpose is to encourage rapid development and deployment of medical products in crisis situations without the threat of unpredictable litigation.
However, while the PREP Act limited access to civil courts, it did not eliminate injury claims altogether. Instead, it directed those claims into a separate administrative compensation system.
That system is the Countermeasures Injury Compensation Program.
Part V: What Is the CICP and How Many COVID Vaccine Injury Claims Have Been Paid?
When COVID-19 vaccines were designated as covered countermeasures under the PREP Act, injury claims were directed into a separate administrative system known as the Countermeasures Injury Compensation Program (CICP).
The CICP is administered by the Health Resources and Services Administration (HRSA) within the U.S. Department of Health and Human Services. It was created to provide limited compensation for injuries caused by certain emergency medical countermeasures deployed during public health emergencies.
Unlike the Vaccine Injury Compensation Program (VICP), the CICP is not a judicial process. There are:
No hearings
No discovery
No cross-examination of experts
No published written decisions
No right to judicial appeal
Claims are reviewed administratively within the agency.
Attorneys’ Fees and Representation
One of the most significant structural differences between the VICP and the CICP concerns legal representation.
Under the VICP, petitioners may recover reasonable attorneys’ fees and litigation costs—even if their claim is ultimately unsuccessful—provided statutory criteria are met. This feature allows injured individuals to obtain legal representation without paying out-of-pocket fees.
The CICP does not pay attorneys’ fees. Claimants may hire an attorney, but any legal fees must be paid personally. Given the medical complexity of vaccine injury claims, this difference can materially affect a claimant’s ability to pursue relief.
What the CICP Provides
If compensation is awarded under the CICP, it may include:
Medical expenses related to the injury
Lost employment income
Death benefits in fatal cases
The CICP does not provide compensation for pain and suffering.
COVID-19 Vaccine Claims in the CICP
According to publicly available data from HRSA, as of January 1, 2026:
Over 14,000 claims have been filed alleging COVID-19 vaccine injury.
More than 6,400 claims have received decisions.
Fewer than 100 claims have been found eligible for compensation.
Fewer than 50 claims have resulted in payment.
Total compensation paid across COVID-related claims remains modest relative to the number of filings.
These figures are drawn from HRSA’s official CICP data reporting page:
https://www.hrsa.gov/cicp/cicp-data
The data show that while thousands of individuals have sought compensation through the CICP for COVID-19 vaccine injuries, only a small fraction of claims have resulted in payment.
Structural Differences Between the CICP and the VICP
The CICP differs from the VICP in several important ways:
The CICP is an administrative review process, not a judicial forum.
There are no published opinions establishing precedent.
There is no discovery process or adversarial hearing.
There is no compensation for pain and suffering.
Attorneys’ fees are not paid.
There is no direct right of appeal to a federal court.
By contrast, the VICP operates within the U.S. Court of Federal Claims, provides written decisions by Special Masters, allows attorney fee recovery, and includes structured procedural safeguards.
Why This Matters
The CICP was not designed to function as a comprehensive vaccine injury compensation system.
It was built as a limited, emergency-response mechanism. It does not provide the procedural safeguards, transparency, or remedies that traditionally accompany serious injury claims.
Most notably, the CICP does not provide compensation for pain and suffering — the primary category of damages in many vaccine injury cases. If an individual suffers catastrophic neurological injury but does not incur significant out-of-pocket medical expenses or wage loss, the CICP may provide little or no compensation at all.
In other words, a person can suffer life-altering harm and still recover nothing.
The CICP also does not provide for attorney fee recovery. As a result, injured individuals must either proceed without legal representation or pay for counsel out of pocket. Given the medical and scientific complexity of vaccine injury claims, this creates a substantial barrier to meaningful participation.
Unlike the VICP, the CICP does not operate within an independent court. Claims are reviewed administratively within the Department of Health and Human Services. There is no hearing before a neutral judicial officer, no discovery process, no cross-examination of experts, no published precedent, and no meaningful judicial appeal. In effect, the same agency responsible for administering the program evaluates the claims brought against it.
When individuals are required to forgo the opportunity to pursue civil litigation in exchange for an administrative compensation program, basic principles of fairness matter. A system that provides no independent fact-finder, no structured appellate review, and limited categories of damages raises serious questions about due process and equitable treatment.
The COVID-19 vaccination campaign placed hundreds of millions of doses into circulation nationwide. The CICP was not built to serve as the exclusive compensation pathway for a program of that magnitude. The pandemic has brought into sharp focus the structural limitations of a system that was never designed to operate at this scale.
Understanding these structural constraints is essential to evaluating whether the current framework adequately serves individuals who suffer rare but serious vaccine-related injuries.
Part VI: What Injuries Have Been Found to Be Associated With COVID-19 Vaccines
n 2024, the National Academies of Sciences, Engineering, and Medicine (NASEM) released a comprehensive consensus report titled Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration. The study was commissioned at the request of the U.S. Department of Health and Human Services (HHS) to evaluate whether available scientific evidence supports a causal relationship between specific COVID-19 vaccines and specific adverse health outcomes.
The committee’s task was not to conduct a broad vaccine safety review or to evaluate public health policy. Instead, it was directed to conduct a structured review of the scientific literature to determine whether the evidence favors acceptance of, favors rejection of, or is inadequate to accept or reject a causal relationship between COVID-19 vaccines and a defined set of medical conditions.
In conducting its review, the committee examined:
Epidemiological studies
Clinical case series
Mechanistic and biological plausibility research
Post-marketing surveillance data
Peer-reviewed medical literature
The committee applied formal evidentiary standards to determine the strength of the available data.
The full report is available here:
https://www.nationalacademies.org/publications/27746
The NASEM Causation Framework
The committee categorized evidence into three primary conclusions:
Evidence favors acceptance of a causal relationship
Evidence favors rejection of a causal relationship
Evidence is inadequate to accept or reject a causal relationship
When the committee concluded that evidence “favors acceptance,” it meant that the available data support a causal link with a high degree of confidence.
When the committee concluded that evidence was “inadequate to accept or reject,” it did not mean that no evidence exists. Rather, it meant that the available studies did not meet the committee’s threshold for affirmatively concluding that causation had been scientifically established or excluded.
This standard reflects a scientific evaluation model that often requires robust epidemiological evidence before declaring a definitive causal relationship.
Conditions for Which Evidence Favors Acceptance
The committee concluded that the evidence favors acceptance of a causal relationship between:
Myocarditis and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna), particularly in certain age and sex groups.
This means that the committee found sufficient scientific evidence to support that these vaccines can cause myocarditis in rare cases.
Conditions With Inadequate Evidence to Accept or Reject
For many other serious conditions, the committee determined that the available evidence was inadequate to accept or reject causation. These included:
Guillain-Barré Syndrome (GBS)
Transverse Myelitis (TM)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Optic Neuritis
Neuromyelitis Optica (NMO)
Immune Thrombocytopenic Purpura (ITP)
Multiple Sclerosis (MS)
Bell’s Palsy
Vasculitis
Various thrombotic and cardiovascular outcomes
For certain vaccine platforms, such as the Janssen vaccine, the committee addressed specific outcomes in greater detail (including Guillain-Barré Syndrome), while for other vaccine platforms and conditions, the evidence did not permit a firm causal conclusion.
Scientific Evaluation vs. Legal Standards
The NASEM committee applied a scientific evidentiary threshold designed to determine whether a causal relationship has been established at the population level.
The Vaccine Injury Compensation Program operates under a different standard.
In vaccine court, petitioners are not required to demonstrate scientific certainty or produce definitive epidemiological proof. Instead, they must establish by a preponderance of the evidence that:
the vaccine can cause the type of injury alleged,
the vaccine did cause the injury in the petitioner’s case, and
a logical sequence of cause and effect links the vaccination to the injury.
This legal framework recognizes that rare, biologically complex injuries may not yet have large-scale epidemiological confirmation but may still be supported by credible medical evidence and case-specific proof.
In practice, the types of medical evidence that may lead a scientific body to conclude that evidence is “inadequate to accept or reject” can, in some cases, be sufficient to satisfy the VICP’s causation-in-fact standard.
That does not mean every such claim would prevail. It does mean that the absence of definitive scientific consensus does not automatically preclude compensation under the VICP.
Why This Distinction Matters
The NASEM report demonstrates two important realities:
Some COVID-19 vaccine-related injuries have been scientifically recognized as causally associated with specific vaccines.
Other serious conditions remain in a gray area where scientific evidence is evolving and not yet definitive.
If COVID-19 vaccines were included in the VICP, conditions such as:
Guillain-Barré Syndrome (GBS)
Transverse Myelitis (TM)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Optic Neuritis
Neuromyelitis Optica (NMO)
Immune Thrombocytopenic Purpura (ITP)
Multiple Sclerosis (MS)
Bell’s Palsy
Vasculitis
Certain thrombotic and cardiovascular conditions
could be evaluated under a judicial framework specifically designed to address scientific uncertainty and individualized medical evidence.
Despite the NASEM findings and the scale of COVID-19 vaccination, neither HHS nor Congress has taken legislative action to incorporate COVID-19 vaccines into the Vaccine Injury Compensation Program. As a result, individuals alleging injury from COVID-19 vaccines remain outside the VICP’s no-fault judicial system and must pursue relief, if at all, through the Countermeasures Injury Compensation Program.
The scientific review has been conducted. The remaining question is whether the legal compensation structure reflects the scientific landscape.
Source
The full report is publicly accessible and provides detailed discussions of study quality, biological plausibility, and the limitations of evidence for each outcome:
National Academies of Sciences, Engineering, and Medicine. Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration. 2024. https://www.nationalacademies.org/publications/27746
Part VII: Why the VICP Is the Logical Forum for COVID Vaccine Injury Claims
The COVID-19 vaccination campaign was unprecedented in scale. Hundreds of millions of doses were administered in the United States in a compressed period of time, supported by federal funding, regulatory acceleration, and public messaging that encouraged widespread uptake.
When vaccination occurs at that scale, rare adverse events are statistically inevitable. That reality does not undermine the overall effectiveness of vaccines. It reflects basic probability: when millions of people receive a medical intervention, even low-incidence complications will appear in a small number of cases.
The legal system must be equipped to respond to that reality.
The Vaccine Injury Compensation Program was created precisely to address rare but serious vaccine injuries within a structured, science-informed, no-fault framework. It was designed to:
eliminate the need to prove product defect or negligence,
allow claims to be evaluated by judicial officers experienced in vaccine causation,
accommodate evolving scientific evidence,
provide compensation for pain and suffering, and
reduce financial barriers by allowing recovery of attorneys’ fees and costs.
The VICP already provides substantial liability protections for manufacturers and administrators of covered vaccines. It balances public health policy with individual redress. It operates within an independent judicial forum, with written decisions, procedural safeguards, and appellate review.
By contrast, the Countermeasures Injury Compensation Program was built as an emergency administrative mechanism. It lacks the procedural features and remedies typically associated with meaningful compensation. It does not provide pain and suffering damages. It does not compensate attorneys’ fees. It does not offer hearings before independent judicial officers. And it provides no direct judicial review.
When individuals are required to forgo civil litigation in exchange for an administrative program, fairness and due process matter. A compensation system must be capable of addressing complex medical claims with transparency, independence, and procedural safeguards.
Including COVID-19 vaccines in the VICP would not signal that vaccines are unsafe. It would signal that Congress recognizes the predictable reality that rare injuries can occur in mass vaccination campaigns and that a structured, judicial compensation system strengthens public trust.
Vaccines can remain safe and effective. Scientific progress can continue. Public health can be preserved.
At the same time, individuals who suffer rare but serious vaccine-related injuries should have access to a compensation system designed to address exactly that kind of harm.
The issue is not whether COVID vaccines should have been deployed. The issue is whether the legal framework that accompanied their deployment adequately accounted for the individuals who would inevitably experience rare adverse events.
The VICP was built for that purpose. The question now is whether it should be extended to fulfill it.